Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Parallel Drug Interaction Study to Evaluate the Effect of a CYP3A Moderate Inducer Efavirenz on the Pharmacokinetics of Quizartinib in Healthy Subjects

NCT04459598 is registered in ClinicalTrials.gov with Daiichi Sankyo Co., Ltd. as lead sponsor.

NCT NCT04459598
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04459598 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Parallel Drug Interaction Study to Evaluate the Effect of a CYP3A Moderate Inducer Efavirenz on the Pharmacokinetics of Quizartinib in Healthy Subjects
Lead sponsor
Daiichi Sankyo Co., Ltd.
Phase
Phase 1
Overall status
Completed
Start date
August 19, 2020
Completion date
October 14, 2020
Enrollment
32 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

drug-drug interaction, healthy subjects, pharmacokinetics, quizartinib